Evotec AG. (3/7/18). "Press Release: Evotec to Attend Upcoming Investor Conferences". Hamburg.

	Organisation	Evotec AG (FSE: EVT, TecDAX)
	Today	Evotec SE (FSE: EVT, MDA X/TecDAX, Nasdaq: EVO)
	Group	Evotec (Group)
	Organisation 2	H.C. Wainwright & Co. LLC
	Group	H.C. Wainwright (Group)
	Product	H.C. Wainwright Global Life Sciences Conference 2018 Monaco
	Product 2	drug discovery services
	Person	Hansen, Gabriele (Evotec 201404 VP Corporate Communications + Investor Relations)

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at the 24th Prior Kapitalmarktkonferenz, Frankfurt, Germany, and at the H.C. Wainwright Global Life Sciences Conference, Monte Carlo, Monaco, and will be attending the Bankhaus Lampe Deutschlandkonferenz, Baden-Baden, Germany, and the 11th Kempen & Co Life Sciences Conference, Amsterdam, The Netherlands.

24th Prior Kapitalmarktkonferenz, Frankfurt, Germany
Date: Tuesday, 13 March 2018
Venue: Frankfurt, Germany

H.C. Wainwright Global Life Sciences Conference, Monte Carlo, Monaco
Date: Monday, 09 April, to Tuesday, 10 April 2018
Venue: Monte Carlo, Monaco

Bankhaus Lampe Deutschlandkonferenz, Baden-Baden, Germany
Date: Wednesday, 18 April, to Friday, 20 April 2018
Venue: Baden-Baden, Germany

11th Kempen & Co Life Sciences Conference, Amsterdam, The Netherlands
Date: Wednesday, 18 April, to Thursday, 19 April 2018
Venue: Amsterdam, The Netherlands

About Evotec AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology and infectious diseases. On this basis, Evotec has built a broad and deep pipeline of more than 80 partnered product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term discovery alliances with partners including Bayer, CHDI, Sanofi or UCB and development partnerships with e.g. with Sanofi in the field of diabetes, with Pfizer in the field of tissue fibrosis and Celgene in the field of neurodegenerative diseases. For additional information please go to www.evotec.com and follow us on Twitter @EvotecAG.

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact Evotec AG:

Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone: +49.(0)40.56081-255, gabriele.hansen@evotec.com

Record changed: 2023-06-05